BITRC

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Biotron Limited

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸƒ Esg

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

3
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Biotron Limited - Rights - Applications Close 18-Nov-2022

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.00

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in BITRC

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in BITRC

N/A
BITRC investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in BITRC also invest in...

Biotron Limited

BIT

Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.

πŸ™Œ Performance (5Yr p.a)

-18.68%

πŸ“Š Share price

$0.01 AUD

🧬 BIOTECHNOLOGY

Find Out More

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

πŸ™Œ Performance (5Yr p.a)

10.00%

πŸ“Š Share price

$16.14 AUD

πŸ’Έ FINANCIALS

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

TECH.AX was created on 2017-04-06 by Global X. The fund's investment portfolio concentrates primarily on information technology equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Morningstar Developed Markets Technology Moat Focus IndexSM (the Index).

πŸ™Œ Performance (5Yr p.a)

6.85%

πŸ“Š Share price

$118.39 AUD

πŸ€– TECHNOLOGY

πŸ‡¦πŸ‡Ί EX AUSTRALIA

🏭 INDUSTRIALS

πŸ’° HIGH DIVIDEND

CNEW.AX was created on 2018-11-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. CNEW.AX gives investors a portfolio of the most fundamentally sound companies in China having the best growth prospects in sectors making up the New Economy, namely technology, health care, consumer staples and consumer discretionary. CNEW.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.

πŸ™Œ Performance (5Yr p.a)

-2.29%

πŸ“Š Share price

$7.11 AUD

VESG.AX was created on 2018-09-11 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Ethically Conscious International Shares Index ETF seeks to track the return of the FTSE Developed ex Australia Choice Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax

πŸ™Œ Performance (5Yr p.a)

13.74%

πŸ“Š Share price

$102.40 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Want more shares? Try these...

BIV

πŸ“Š Share price

$0.00 AUD